At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 10 enrolled
Drug / intervention
Rapamunedrug
Likely dose
Rapamune 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway (CARPE DIEM)
The University of Texas Health Science Center at San Antonio·interventional·Posted Dec 16, 2019·Updated Jan 8, 2025
In Brief
A Early Phase 1 clinical trial evaluating Rapamune for Cognitive Impairment, Mild and Alzheimer Disease. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCognitive Impairment, Mild, Alzheimer Disease
CountriesUnited States
Timeline
Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartJun 2020
Primary CompletionJan 2022
TodayJul 2026
First PostedDec 16, 2019
Enrollment StartJun 1, 2020
Primary CompletionJan 13, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.5 years ago
Interventions
Rapamunedrug
Sirolimus 1mg capsules